Table 1.
Clinical parameters of MM patients
| Patient | Age | Sex | Type of Ig | Clinical stage | Medical history | Lenalidomide refractory | ||
|---|---|---|---|---|---|---|---|---|
| D&S | ISS | R-ISS | ||||||
| S1 | 68 | F | IgA-κ | IIIA | III | III | Newly diagnosed | No |
| S2 | 78 | M | IgG-λ | IIA | II | II | Newly diagnosed | No |
| S3 | 78 | M | IgG-κ | IIIA | III | N/A | Newly diagnosed | No |
| S4 | 46 | M | IgG-λ | IIIA | III | III | Newly diagnosed | No |
| S5 | 66 | M | IgG-κ | IIA | I | II | Newly diagnosed | No |
| S6 | 51 | F | IgG-λ | IIA | II | II | CyBorD, HDCY, BD, MEL, autoPBSCT | No |
| R1 | 56 | M |
IgG-κ/ BJP-κ |
IA | I | N/A | VRd | Yes |
| R2 | 55 | F | IgA-λ | IIA | I | II | VRd, VP16, MEL, autoPBSCT, biweeklyBor, LEN maintenance, DRd, VTDPACE, DCEP, KRd | Yes |
| R3 | 80 | M | IgA-κ | IIA | I | N/A | CyBorD, Bor biweekly, VTd, VRd, HDCY, MEL, auto PBSCT | Yes |
| R4 | 73 | F | BJP-λ | IIIB | III | III | Ld, Eld, DVd, PCd | Yes |
| R5 | 62 | M | IgG-κ | IIIA | III | II | BD, VRd | Yes |
| R6 | 76 | M | IgA-λ | IIIA | II | II | CyBorD, VRd, LEN maintenance, DVd, PCd, KRd, Kd | Yes |
CyBorD; cyclophosphamide, bortezomib, dexamethasone. HDCY; High dose cyclophosphamide. BD; bortezomib, dexamethasone. MEL; melphalan. PBSCT; peripheral blood stem cell transplantation. VRd; bortezomib, lenalidomide, dexamethasone. VP-16; etoposide. Bor; bortezomib. LEN; lenalidomide. DRd; daratumumab, lenalidomide, dexamethasone. VTD-PACE; bortezomib, thalidomide, dexamethasone, cisplatin, doxorubicin, cyclophosphamide, etoposide. DCEP; dexamethasone, cyclophosphamide, etoposide, cisplatin. KRd; carfilzomib, lenalidomide, dexamethasone. VTd; bortezomib, thalidomide, dexamethasone. Ld; lenalidomide, dexamethasone. Eld; elotuzumab, lenalidomide, dexamethasone. DVd; daratumumab, bortezomib, dexamethasone. PCd; pomalidomide, cyclophosphamide, dexamethasone. Kd; carfilzomib, dexamethasone. D&S:Durie-Salmon staging. ISS:International Staging System. R-ISS:Revised International Staging System